Breast cancer affect around 52 000 women in France each year. Amongst them, 7% are less than 40 years old and 2% are in between 25 and 35 years old. Significant therapeutic advances have improved the prognostic of these patients. They will all most likely to received chemotherapy. Despite the fact that chemotherapy has many side effects, these women do question the impact of the treatment on their ability to procreate. On 06/08/04 law basis, each patient is allowed to preserve gametes or germinal tissues when medical care potentially affect fertility. Functional evaluation of ovarian reserve could help comprehend new chemotherapy protocols, provide fertility information, and help individualize fertility preservation supports. Principal objective is to ensure the absence of ovarian stimulation's side effects and assess chemotherapy effects on child carrying potential.
Study Type
OBSERVATIONAL
Enrollment
135
Oscar Lambret Center
Lille, Hauts-de-France, France
change from baseline of Anti Mullerian Hormone (AMH) rate to different time points until 24 months
variation of percentages of AMH rate compared to baseline - Observe sequential chemotherapy on ovarian follicular content
Time frame: baseline, Day 1 of Cycle 2, Day 1 of Cycle 4, Day 1 of Cycle 6, 3 months, 6 months, 9 months, 12 months, 24 months
change from baseline of account of antral follicles (CFA) rate to different time points until 24 months
variation of percentages of CFA rate compared to baseline - Observe sequential chemotherapy on ovarian follicular content
Time frame: baseline, Day 1 of Cycle 2, Day 1 of Cycle 4, Day 1 of Cycle 6, 3 months, 6 months, 9 months, 12 months, 24 months
amenorrhea chemotherapeutically induced (weeks)
observe chemotherapy induced amenorrhea frequency and duration of amenorrhea
Time frame: 4 years
correlation between amenorrhea duration and oncologic outcome (overall and free disease survival)
collection of amenorrhea duration (weeks)
Time frame: 4 years
correlation between ovarian stimulation safety and oncologic outcome (overall and free disease survival)
toxicity assessment
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.